Tags

Type your tag names separated by a space and hit enter

[Effects of antiparkinsonian drug hemantane on the level and metabolism of biogenic monoamines in brain structures of C57BL/6 mice].
Eksp Klin Farmakol. 2009 Jan-Feb; 72(1):64-7.EK

Abstract

Hemantane (N-adamant-2-yl-hexamethyleneimine hydrochlortide) is a new antiparkinsonian drug showing a broad activity spectrum, being superior to the reference drug amantadine in some tests. The effects of hemantane on the levels of biogenic amines and their metabolites in the striatum, frontal cortex, and hippocampus have been studied in C57BL/6 mice. It was found that a single administration of hemantane (20 mg/kg, i.p.) decreased the concentration of DOPA, serotonin, and its metabolite in mice striatum, gently inhibited the synthesis of dopamine in mice striatum, and influenced the HVA/DA balance in frontal cortex homogenates.

Authors

Abaimov DA
No affiliation info available
Zimin IA
No affiliation info available
Kudrin VS
No affiliation info available
Kovalev GI
No affiliation info available

MeSH

AdamantaneAnimalsAntiparkinson AgentsBiogenic MonoaminesCorpus StriatumFrontal LobeHippocampusMaleMiceMice, Inbred C57BL

Pub Type(s)

English Abstract
Journal Article

Language

rus

PubMed ID

19334515

Citation

Abaimov, D A., et al. "[Effects of Antiparkinsonian Drug Hemantane On the Level and Metabolism of Biogenic Monoamines in Brain Structures of C57BL/6 Mice]." Eksperimental'naia I Klinicheskaia Farmakologiia, vol. 72, no. 1, 2009, pp. 64-7.
Abaimov DA, Zimin IA, Kudrin VS, et al. [Effects of antiparkinsonian drug hemantane on the level and metabolism of biogenic monoamines in brain structures of C57BL/6 mice]. Eksp Klin Farmakol. 2009;72(1):64-7.
Abaimov, D. A., Zimin, I. A., Kudrin, V. S., & Kovalev, G. I. (2009). [Effects of antiparkinsonian drug hemantane on the level and metabolism of biogenic monoamines in brain structures of C57BL/6 mice]. Eksperimental'naia I Klinicheskaia Farmakologiia, 72(1), 64-7.
Abaimov DA, et al. [Effects of Antiparkinsonian Drug Hemantane On the Level and Metabolism of Biogenic Monoamines in Brain Structures of C57BL/6 Mice]. Eksp Klin Farmakol. 2009 Jan-Feb;72(1):64-7. PubMed PMID: 19334515.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Effects of antiparkinsonian drug hemantane on the level and metabolism of biogenic monoamines in brain structures of C57BL/6 mice]. AU - Abaimov,D A, AU - Zimin,I A, AU - Kudrin,V S, AU - Kovalev,G I, PY - 2009/4/2/entrez PY - 2009/4/2/pubmed PY - 2009/6/2/medline SP - 64 EP - 7 JF - Eksperimental'naia i klinicheskaia farmakologiia JO - Eksp Klin Farmakol VL - 72 IS - 1 N2 - Hemantane (N-adamant-2-yl-hexamethyleneimine hydrochlortide) is a new antiparkinsonian drug showing a broad activity spectrum, being superior to the reference drug amantadine in some tests. The effects of hemantane on the levels of biogenic amines and their metabolites in the striatum, frontal cortex, and hippocampus have been studied in C57BL/6 mice. It was found that a single administration of hemantane (20 mg/kg, i.p.) decreased the concentration of DOPA, serotonin, and its metabolite in mice striatum, gently inhibited the synthesis of dopamine in mice striatum, and influenced the HVA/DA balance in frontal cortex homogenates. SN - 0869-2092 UR - https://www.unboundmedicine.com/medline/citation/19334515/[Effects_of_antiparkinsonian_drug_hemantane_on_the_level_and_metabolism_of_biogenic_monoamines_in_brain_structures_of_C57BL/6_mice]_ DB - PRIME DP - Unbound Medicine ER -